Azithromycin suppresses proliferation, interleukin production and mitogen-activated protein kinases in human peripheral-blood mononuclear cells stimulated with bacterial superantigen

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 10, 2011, Pages 1320-1326

  Hiwatashi, Yoko ^a,b   Maeda, Masaki ^c   Fukushima, Hisayo ^a   Onda, Kenji ^a   Tanaka, Sachiko ^a   Utsumi, Hiroya ^d   Hirano, Toshihiko ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c Bohsei Pharmacy   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

azithromycin; cytokines; ERK activity; JNK activity; peripheral blood mononuclear cells

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; MACROLIDE; MITOGEN ACTIVATED PROTEIN KINASE; PREDNISOLONE; ROXITHROMYCIN; STRESS ACTIVATED PROTEIN KINASE; TOXIC SHOCK SYNDROME TOXIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION INHIBITION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOREGULATION; IN VITRO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS INHIBITION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIA; CELL LINE; CELL PROLIFERATION; CONCANAVALIN A; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROTOXINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; INTERLEUKINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKOCYTES, MONONUCLEAR; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE FRAGMENTS; PREDNISOLONE; SUPERANTIGENS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 80052564426     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01343.x     Document Type: Article

References (31)

1. Taylor JE, et al,. Group A streptococcal antigens and superantigens in the pathogenesis of autoimmune arthritis. Eur J Clin Invest 1994; 24: 511-521. (Pubitemid 24251577)
2. Hauk PJ, et al,. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol 2000; 105: 782-787. (Pubitemid 30226454)
3. Rasmussen JE,. The relationship between infection with group A beta hemolytic streptococci and the development of psoriasis. Pediatr Infect Dis J 2000; 19: 153-154. (Pubitemid 30111413)
4. Fakhri S, et al,. Microbial superantigens induce glucocorticoid receptor beta and steroid resistance in a nasal explant model. Laryngoscope 2004; 114: 887-892. (Pubitemid 38625543)
5. Culić O, et al,. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209-229.
6. Tamaoki J, et al,. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004; 117: 5S-11S.
7. Tsai WC, Standiford TJ,. Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models. Curr Pharm Des 2004; 10: 3081-3093. (Pubitemid 39242903)
8. Komine M, Tamaki K,. An open trial of oral macrolide treatment for psoriasis vulgaris. J Dermatol 2000; 27: 508-512.
9. Ohshima A, et al,. CD8+ cell changes in psoriasis associated with roxithromycin-induced clinical improvement. Eur J Dermatol 2001; 11: 410-415. (Pubitemid 32801335)
10. Norris D,. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 2005; 53: 17-25.
11. Kamogawa S, et al,. Suppressive efficacies of roxithromycin against human peripheral-blood mononuclear cells stimulated with hemolytic streptococci superantigen. Eur J Pharmacol 2009; 602: 439-447.
12. Hirano T, et al,. Individual pharmacodynamics assessed by antilymphocyte action predicts clinical cyclosporine-efficacy in psoriasis. Clin Pharmacol Ther 1998; 63: 465-470. (Pubitemid 28214970)
13. Hirano T,. Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine. Int Immunopharmacol 2007; 7: 3-22. (Pubitemid 44856394)
14. Hirano T, et al,. Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis and psoriasis: possible implications for individual therapeutic efficacy. Clin Pharmacol Ther 1997; 62: 652-664. (Pubitemid 28068069)
15. Hirano T, et al,. Clinical impact of cyclosporine cellular- pharmacodynamics in minimal change nephrotic syndrome. Clin Pharmacol Ther 2000; 68: 532-540.
16. Fukushima H, et al,. The role of immune response to Staphylococcus aureus superantigens and disease severity to the sensitivity to tacrolimus in atopic dermatitis. Int Arch Allergy Immunol 2006; 141: 281-289. (Pubitemid 44597747)
17. Kadota J, et al,. Antibiotic-induced apoptosis in human activated peripheral lymphocytes. Int J Antimicrob Agents 2005; 25: 216-220. (Pubitemid 40292751)
18. Ishimatsu Y, et al,. Macrolide antibiotics induce apoptosis of human peripheral lymphocytes in vitro. Int J Antimicrob Agents 2004; 24: 247-253.
19. Mizunoe S, et al,. Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL. Int Immunopharmacol 2004; 4: 1201-1217.
20. Kudoh S, et al,. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 1987; 25: 632-642 (in Japanese). (Pubitemid 17141772)
21. Polat M, et al,. Efficacy of erythromycin for psoriasis vulgaris. Clin Exp Dermatol 2007; 32: 295-297. (Pubitemid 46495798)
22. Puri SK, Lassman HB,. Roxithromycin: a pharmacokinetic review of a macrolide. J Antimicrob Chemother 1987; 20: 89-100. (Pubitemid 18003053)
23. Wise R, et al,. Pharmacokinetics and tissue penetration of roxithromycin after multiple dosing. Antimicrob Agents Chemother 1987; 31: 1051-1053. (Pubitemid 17099577)
24. Koyama M, et al,. Absorption, metabolism and excretion of RU 28965 in human. Chemotherapy 1988; 36: 164-183.
25. Hand WL, et al,. Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1987; 31: 1553-1557. (Pubitemid 17140810)
26. Galioto GB, et al,. Roxithromycin disposition in tonsils after single and repeated administrations. Antimicrob Agents Chemother 1988; 32: 1461-1463.
27. Fukushima H, et al,. Staphylococcus aureus superantigens decreases FKBP51mRNA expression and cell response to suppressive efficacy of glucocorticoid in human peripheral blood mononuclear cells: possible implication of MAPK pathways. Eur J Pharmacol 2007; 570: 222-228. (Pubitemid 47247674)
28. Uchiyama T, et al,. Activation of murine T cells by toxic shock syndrome toxin-1. The toxin-binding structures expressed on murine accessory cells are MHC class II molecules. J Immunol 1989; 143: 3175-3182. (Pubitemid 20010142)
29. Li LB, et al,. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. J Allergy Clin Immunol 2004; 114: 1059-1069.
30. Edmead CE, et al,. Induction of activator protein (AP)-1 and nuclear factor-kappaB by CD28 stimulation involves both phosphatidylinositol 3-kinase and acidic sphingomyelinase signals. J Immunol 1996; 157: 3290-3297. (Pubitemid 126449138)
31. Koike T, et al,. A novel ERK-dependent signaling process that regulates interleukin-2 expression in a late phase of T cell activation. J Biol Chem 2003; 278: 15685-15692. (Pubitemid 36799679)